Results 21 to 30 of about 14,917 (240)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

Therapeutic Advances in Hematology, 2021
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine).
Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno, Eduardo-Rodriguez Arboli, Laila Abdel-kader Martín   +4 more
doaj   +1 more source

DNA methylation at tobacco telomeric sequences [PDF]

, 2011
Majerová et al. (Plant Mol Biol, 2011) have recently reported that a considerable fraction of cytosines at tobacco telomeres is methylated. Although the data presented in this report indicate that tobacco telomeric sequences undergo certain levels of DNA
Vaquero Sedas, María Isabel, Vega Palas, Miguel Ángel   +1 more
core   +1 more source

Hypomethylating agents after allogeneic blood stem cell transplantation [PDF]

Stem Cell Investigation, 2016
Allogeneic blood stem cell transplantation (allo-SCT) is a potentially curative treatment for patients with myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but relapse remains the major cause of treatment failure. So far, therapeutic options for patients with AML or MDS who relapse after allo-SCT generally
Thomas, Schroeder, Christina, Rautenberg, Rainer, Haas, Guido, Kobbe   +3 more
openaire   +2 more sources

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Acta Medica Bulgarica, 2020
Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Varbanova V., Anastasova-Postadzhiyan A., Nedeva A., Nikolov I., Kindekov I., Kuyumdzhieva Y., Petkova N., Vikentieva E., Lubomir M., Raynov J.   +9 more
doaj   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Oral hypomethylating agents: beyond convenience in MDS

Hematology, 2021
AbstractOral hypomethylating agents (HMAs) represent a substantial potential boon for patients with myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per month to an infusion clinic to receive therapy. For patients who respond to treatment, ongoing monthly maintenance visits represent a considerable burden to quality of
openaire   +3 more sources

Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]

, 2014
Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Cashen, Amanda F., Malik, Priya
core   +3 more sources

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia [PDF]

Cell Cycle, 2011
The deregulation of the DNA damage response (DDR) can contribute to leukemogenesis and favor the progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML). Since hypomethylating agent, notably azacitidine, constitute an efficient therapy for patients with high-risk MDS, we assessed whether such compounds can activate the DDR in ...
Thépot, Sylvain, Lainey, Elodie, Cluzeau, Thomas, Sébert, Marie, Leroy, Carole, Adès, Lionel, Tailler, Maximilien, Galluzzi, Lorenzo, Baran-Marszak, Fanny, Roudot, Hervé, Eclache, Virginie, Gardin, Claude, de Botton, Stéphane, Auberger, Patrick, Fenaux, Pierre, Kroemer, Guido, Boehrer, Simone   +16 more
openaire   +3 more sources

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

Haematologica, 2020
In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges. Optimal front-line therapies for older
Chetasi Talati, Varun C Dhulipala, Mar tine Extermann, Najla Al Ali, Jongphil Kim, Rami Komrokji, Kendra Sweet, Andrew Kuykendall, Marina Sehovic, Tea Reljic, Benjamin Djulbegovic, Jeffrey E. Lancet   +11 more
doaj   +1 more source

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia

Clinical Case Reports, 2023
Key Clinical Message Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results.
Anwarul Islam
doaj   +1 more source